Mepolizumab - GlaxoSmithKline

Drug Profile

Mepolizumab - GlaxoSmithKline

Alternative Names: 240563; Bosatria; Mepolizamab; Nucala; SB-240563

Latest Information Update: 05 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; McMaster University; National Institute of Allergy and Infectious Diseases
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypereosinophilic syndrome; Churg-Strauss syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Registered Churg-Strauss syndrome
  • Preregistration Chronic obstructive pulmonary disease
  • Phase III Hypereosinophilic syndrome; Nasal polyps
  • Phase II Atopic dermatitis
  • No development reported Eosinophilic oesophagitis

Most Recent Events

  • 12 Dec 2017 Registered for Churg-Strauss syndrome (Adjunctive treatment) in USA (SC)
  • 12 Dec 2017 Mepolizumab received priority review status for Churg-Strauss syndrome in USA, before December 2017
  • 30 Nov 2017 GlaxoSmithKline completes a phase III trial in Asthma (Adjunctive treatment, In adolescents, In adults) in Germany, Australia, Canada, Russia and United Kingdom, USA and Sweden (SC) (NCT03099096) (EudraCT2016-001832-36)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top